Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016

Karlijn H G Rutten; Reinier A P Raymakers; Bouke P C Hazenberg; Hans L A Nienhuis; Edo Vellenga; Monique C Minnema

doi:10.1080/13506129.2018.1536043

Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016

Karlijn H G Rutten, Reinier A P Raymakers, Bouke P C Hazenberg, Hans L A Nienhuis, Edo Vellenga, Monique C Minnema

Research output: Contribution to journal › Article › Academic › peer-review

7 Citations (Scopus)

233 Downloads (Pure)

Abstract

Background: Although survival has improved in recent decades, the short-term prognosis of patients with immunoglobulin light chain (AL) amyloidosis remains grim. We aimed to assess overall survival (OS) of AL amyloidosis patients by comparing cohorts in two consecutive time periods.Methods: Data were collected and compared on 126 patients from two tertiary referral centres in The Netherlands during the time periods 2008-2012 and 2013-2016.Results: There was a non-significant trend to improved 6-month OS in the last cohort (78% vs. 67%, p=.216, crude odds ratio 1.66, 95%CI 0.74-3.70, adjusted odds ratio 2.22, 95%CI 0.88-5.56). Patients in this cohort had higher Mayo risk scores (stage III 40% vs. 24%, p

Original language	English
Pages (from-to)	227-233
Number of pages	7
Journal	Amyloid
Volume	25
Issue number	4
DOIs	https://doi.org/10.1080/13506129.2018.1536043
Publication status	Published - 2018

Keywords

AL amyloidosis
survival
prognosis
time trend
LIGHT-CHAIN AMYLOIDOSIS
STEM-CELL TRANSPLANTATION
IMPROVED OUTCOMES
STAGING SYSTEM
MANAGEMENT
PROGNOSIS
MELPHALAN

Access to Document

10.1080/13506129.2018.1536043Licence: CC BY-NC-ND

Haematological response and overall survival intwo consecutive Dutch patient cohorts with ALamyloidosis diagnosed between 2008 and 2016Final publisher's version, 1.45 MBLicence: CC BY-NC-ND

Handle.net

Persistent link

Cite this

@article{f924cbc907b7493d95a81ef073fbfcff,

title = "Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016",

abstract = "Background: Although survival has improved in recent decades, the short-term prognosis of patients with immunoglobulin light chain (AL) amyloidosis remains grim. We aimed to assess overall survival (OS) of AL amyloidosis patients by comparing cohorts in two consecutive time periods.Methods: Data were collected and compared on 126 patients from two tertiary referral centres in The Netherlands during the time periods 2008-2012 and 2013-2016.Results: There was a non-significant trend to improved 6-month OS in the last cohort (78% vs. 67%, p=.216, crude odds ratio 1.66, 95%CI 0.74-3.70, adjusted odds ratio 2.22, 95%CI 0.88-5.56). Patients in this cohort had higher Mayo risk scores (stage III 40% vs. 24%, p",

keywords = "AL amyloidosis, survival, prognosis, time trend, LIGHT-CHAIN AMYLOIDOSIS, STEM-CELL TRANSPLANTATION, IMPROVED OUTCOMES, STAGING SYSTEM, MANAGEMENT, PROGNOSIS, MELPHALAN",

author = "Rutten, {Karlijn H G} and Raymakers, {Reinier A P} and Hazenberg, {Bouke P C} and Nienhuis, {Hans L A} and Edo Vellenga and Minnema, {Monique C}",

year = "2018",

doi = "10.1080/13506129.2018.1536043",

language = "English",

volume = "25",

pages = "227--233",

journal = "Amyloid",

issn = "1350-6129",

publisher = "Taylor & Francis Ltd",

number = "4",

}

TY - JOUR

T1 - Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016

AU - Rutten, Karlijn H G

AU - Raymakers, Reinier A P

AU - Hazenberg, Bouke P C

AU - Nienhuis, Hans L A

AU - Vellenga, Edo

AU - Minnema, Monique C

PY - 2018

Y1 - 2018

N2 - Background: Although survival has improved in recent decades, the short-term prognosis of patients with immunoglobulin light chain (AL) amyloidosis remains grim. We aimed to assess overall survival (OS) of AL amyloidosis patients by comparing cohorts in two consecutive time periods.Methods: Data were collected and compared on 126 patients from two tertiary referral centres in The Netherlands during the time periods 2008-2012 and 2013-2016.Results: There was a non-significant trend to improved 6-month OS in the last cohort (78% vs. 67%, p=.216, crude odds ratio 1.66, 95%CI 0.74-3.70, adjusted odds ratio 2.22, 95%CI 0.88-5.56). Patients in this cohort had higher Mayo risk scores (stage III 40% vs. 24%, p

AB - Background: Although survival has improved in recent decades, the short-term prognosis of patients with immunoglobulin light chain (AL) amyloidosis remains grim. We aimed to assess overall survival (OS) of AL amyloidosis patients by comparing cohorts in two consecutive time periods.Methods: Data were collected and compared on 126 patients from two tertiary referral centres in The Netherlands during the time periods 2008-2012 and 2013-2016.Results: There was a non-significant trend to improved 6-month OS in the last cohort (78% vs. 67%, p=.216, crude odds ratio 1.66, 95%CI 0.74-3.70, adjusted odds ratio 2.22, 95%CI 0.88-5.56). Patients in this cohort had higher Mayo risk scores (stage III 40% vs. 24%, p

KW - AL amyloidosis

KW - survival

KW - prognosis

KW - time trend

KW - LIGHT-CHAIN AMYLOIDOSIS

KW - STEM-CELL TRANSPLANTATION

KW - IMPROVED OUTCOMES

KW - STAGING SYSTEM

KW - MANAGEMENT

KW - PROGNOSIS

KW - MELPHALAN

U2 - 10.1080/13506129.2018.1536043

DO - 10.1080/13506129.2018.1536043

M3 - Article

C2 - 30513220

SN - 1350-6129

VL - 25

SP - 227

EP - 233

JO - Amyloid

JF - Amyloid

IS - 4

ER -